세계의 트랜스티레틴 아밀로이드 심근증(ATTR-CM) 치료 시장 보고서(2025년)

Transthyretin amyloid cardiomyopathy (ATTR-CM) treatment involves medical therapies and interventions aimed at managing this progressive, life-threatening condition, which is caused by the accumulation of misfolded transthyretin (TTR) proteins in the heart. This buildup leads to restrictive cardiomyopathy and heart failure.

The main treatment types for ATTR-CM include transthyretin stabilizers, nonsteroidal anti-inflammatory drugs (NSAIDs), RNAi therapy, and other treatments. Transthyretin stabilizers work by preventing the misfolding of transthyretin proteins, thereby reducing amyloid deposits and slowing the progression of the disease. Clinical indications for treatment include wild-type ATTR amyloidosis and hereditary ATTR amyloidosis. These treatments are used by various end users, including hospitals, home care settings, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market research report is one of a series of new reports from The Business Research Company that provides transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market statistics, including the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry global market size, regional shares, competitors with the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market share, detailed transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment industry. This transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The transthyretin amyloid cardiomyopathy (attr-cm) treatment market size has grown exponentially in recent years. It will grow from $10.36 billion in 2024 to $13.29 billion in 2025 at a compound annual growth rate (CAGR) of 28.2%. The growth in the historic period can be attributed to rising prevalence of transthyretin amyloid cardiomyopathy, increasing prevalence of transthyretin amyloidosis among geriatric patients, increasing awareness among healthcare professionals and patients, growth in awareness and improvement of healthcare services.

The transthyretin amyloid cardiomyopathy (attr-cm) treatment market size is expected to see exponential growth in the next few years. It will grow to $35.5 billion in 2029 at a compound annual growth rate (CAGR) of 27.8%. The growth in the forecast period can be attributed to increasing prevalence of transthyretin amyloidosis, rise in diagnosis of neuropathic disorders, rising demographic of aging population, increase in demand for specific drugs for treating symptoms of the rare disorder, increasing demand for healthcare. Major trends in the forecast period include new diagnostic technologies, development of innovative techniques for the therapy management, innovative and targeted treatments for transthyretin amyloidosis, advancements in diagnostics techniques, cardiac MRI techniques.

The forecast of 27.8% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. cardiology centers by driving up the cost of tafamidis therapies and cardiac MRI contrast agents sourced from Switzerland and Belgium, exacerbating treatment expenses for this progressive fatal condition. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of chronic diseases is expected to drive the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in the future. Chronic diseases are long-lasting conditions that progress slowly and can last for a year or more, often requiring ongoing medical care. The rise in chronic diseases is due to factors such as aging populations, sedentary lifestyles, unhealthy diets, rising obesity rates, and exposure to environmental pollutants. Treatment for transthyretin amyloid cardiomyopathy helps stabilize the transthyretin protein, reduce amyloid buildup, improve heart function, and alleviate symptoms, which helps in managing related chronic conditions. For example, in September 2023, the World Health Organization reported that 41 million deaths annually are caused by non-communicable diseases (NCDs) or chronic diseases, accounting for 74% of global deaths. Among these, 17.9 million were due to cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Therefore, the growing prevalence of chronic diseases is fueling the growth of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Companies in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are also focusing on developing innovative treatments, such as oral medications to target and stabilize transthyretin (TTR) proteins or reduce amyloid fibril buildup in the heart. Oral prescription medications are drugs that are taken by mouth, usually in the form of tablets, capsules, or liquid solutions, as prescribed by a healthcare provider. For instance, in November 2024, BridgeBio Pharma Inc., a U.S.-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Attruby (acoramidis), an oral treatment for adults with transthyretin amyloid cardiomyopathy (ATTR-CM). This medication stabilizes the TTR protein, reducing heart-related deaths and hospitalizations. Clinical trials have demonstrated that it is well-tolerated and provides rapid benefits by targeting the root cause of the disease.

In January 2022, AstraZeneca Plc, a UK-based pharmaceutical company, entered into a partnership with Neurimmune AG, a Switzerland-based biopharmaceutical company. Together, they aim to develop NI006 for the treatment of ATTR-CM, targeting amyloid deposits in the heart. This collaboration seeks to address the growing need for effective treatments for transthyretin amyloid cardiomyopathy (ATTR-CM).

Major players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG.

North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in transthyretin amyloid cardiomyopathy (ATTR-CM) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The transthyretin amyloid cardiomyopathy (ATTR-CM) market consists of revenues earned by entities by providing services such as diagnosis and screening services, pharmaceutical and drug therapies, patient monitoring and disease management, specialized treatment centers and hospital services. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloid cardiomyopathy (ATTR-CM) market also includes sales of tafamidis, patisiran, vutrisiran, and acoramidis. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on transthyretin amyloid cardiomyopathy (attr-cm) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for transthyretin amyloid cardiomyopathy (attr-cm) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The transthyretin amyloid cardiomyopathy (attr-cm) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Transthyretin Stabilizers; Nonsteroidal Anti-inflammatory Drugs (NSAID); RNAi Therapy; Other Types
• 2) By Indication: Wild type ATTR Amyloidosis; Hereditary ATTR amyloidosis
• 3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Transthyretin Stabilizers: Tafamidis; Diflunisal
• 2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin; Ibuprofen; Other NSAIDs
• 3) By RNAi Therapy: Patisiran; Vutrisiran
• 4) By Other Types: Gene Silencing Therapies; Immunotherapy Approaches; Emerging Small Molecule Therapies
• Companies Mentioned: Pfizer Inc.; Bayer AG.; AstraZeneca Plc; GlaxoSmithKline Plc.; Takeda Pharmaceutical Company Limited; Novo Nordisk A/S; Regeneron Pharmaceuticals Inc.; MedStar Health Inc; Alnylam Pharmaceuticals Inc; Ionis Pharmaceuticals Inc.; Akcea Therapeutics Inc; BridgeBio Pharma Inc.; Prothena Corporation plc; Intellia Therapeutics Inc.; Alexion Pharmaceuticals Inc.; Neurimmune Holding AG; SOM Biotech S.L; Corino Therapeutics Inc; Eidos Therapeutics Inc; CRISPR Therapeutics AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Characteristics

3. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Trends And Strategies

4. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Growth Rate Analysis
• 5.4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Total Addressable Market (TAM)

6. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Segmentation

• 6.1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Transthyretin Stabilizers
• Nonsteroidal Anti-inflammatory Drugs (NSAID)
• RNAi Therapy
• Other Types
• 6.2. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wild type ATTR Amyloidosis
• Hereditary ATTR amyloidosis
• 6.3. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Transthyretin Stabilizers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tafamidis
• Diflunisal
• 6.5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aspirin
• Ibuprofen
• Other NSAIDs
• 6.6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of RNAi Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Patisiran
• Vutrisiran
• 6.7. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Silencing Therapies
• Immunotherapy Approaches
• Emerging Small Molecule Therapies

7. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Regional And Country Analysis

• 7.1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 8.1. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 9.1. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 9.2. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 10.1. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 11.1. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 11.2. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 12.1. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 13.1. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 14.1. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 14.2. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 15.1. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 15.2. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 16.1. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 17.1. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 18.1. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 19.1. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 20.1. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 21.1. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 21.2. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 22.1. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 23.1. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 23.2. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 24.1. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 24.2. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 25.1. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 25.2. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 26.1. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 26.2. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 27.1. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 28.1. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 28.2. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

• 29.1. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Overview
• 29.2. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Landscape
• 30.2. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline Plc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

31. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Other Major And Innovative Companies

• 31.1. Novo Nordisk A/S
• 31.2. Regeneron Pharmaceuticals Inc.
• 31.3. MedStar Health Inc
• 31.4. Alnylam Pharmaceuticals Inc
• 31.5. Ionis Pharmaceuticals Inc.
• 31.6. Akcea Therapeutics Inc
• 31.7. BridgeBio Pharma Inc.
• 31.8. Prothena Corporation plc
• 31.9. Intellia Therapeutics Inc.
• 31.10. Alexion Pharmaceuticals Inc.
• 31.11. Neurimmune Holding AG
• 31.12. SOM Biotech S.L
• 31.13. Corino Therapeutics Inc
• 31.14. Eidos Therapeutics Inc
• 31.15. CRISPR Therapeutics AG

32. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

34. Recent Developments In The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

35. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer